BCL2 and B-cell chronic lymphocytic leukemia: Lisaftoclax was designed through computational modeling and selectively binds to BCL-2 (Ki < 0.1 nmol/L), disrupting BCL-2 complexes and demonstrating potent antitumor activity in CLL patients’ sample and preclinical models, including ibrutinib-relapsed malignancies [114].